(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Hepatología bioquímica > DA - CIMA - Terapia génica y Hepatología - Hepatología bioquímica - Artículos de revista >

Methylthioadenosine reverses brain autoimmune disease
Autor(es) : Moreno, B. (Beatriz)
Hevia, H. (Henar)
Santamaria, M. (Mónica)
Sepulcre, J. (Jorge)
Muñoz, J. (Javier)
Garcia-Trevijano, E.R. (Elena R.)
Berasain, C. (Carmen)
Corrales, F.J. (Fernando José)
Avila, M.A. (Matías Antonio)
Villoslada, P. (Pablo)
Palabras clave : Encephalomyelitis, Autoimmune, Experimental/prevention & control
Immunologic Factors/therapeutic use
Multiple Sclerosis/drug therapy
Thionucleosides/therapeutic use
Fecha incorporación: 2006
Editorial : Wiley-Blackwell
Versión del editor: http://onlinelibrary.wiley.com/doi/10.1002/ana.20895/abstract
ISSN: 1531-8249
Cita: Moreno B, Hevia H, Santamaria M, Sepulcre J, Munoz J, Garcia-Trevijano ER, et al. Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 2006 Sep;60(3):323-334.
Resumen
OBJECTIVE: To assess the immunomodulatory activity of methylthioadenosine (MTA) in rodent experimental autoimmune encephalomyelitis (EAE) and in patients with multiple sclerosis. METHODS: We studied the effect of intraperitoneal MTA in the acute and chronic EAE model by quantifying clinical and histological scores and by performing immunohistochemistry stains of the brain. We studied the immunomodulatory effect of MTA in lymphocytes from EAE animals and in peripheral blood mononuclear cells from healthy control subjects and multiple sclerosis patients by assessing cell proliferation and cytokine gene expression, by real-time polymerase chain reaction, and by nuclear factor-kappaB modulation by Western blot. RESULTS: We found that MTA prevents acute EAE and, more importantly, reverses chronic-relapsing EAE. MTA treatment markedly inhibited brain inflammation and reduced brain damage. Administration of MTA suppressed T-cell activation in vivo and in vitro, likely through a blockade in T-cell signaling resulting in the prevention of inhibitor of kappa B (IkappaB-alpha) degradation and in the impaired activation transcription factor nuclear factor-kappaB. Indeed, MTA suppressed the production of proinflammatory genes and cytokines (interferon-gamma, tumor necrosis factor-alpha, and inducible nitric oxide synthase) and increased the production of antiinflammatory cytokines (interleukin-10). INTERPRETATION: MTA has a remarkable immunomodulatory activity and may be beneficial for multiple sclerosis and other autoimmune diseases.
Enlace permanente: http://hdl.handle.net/10171/21521
Aparece en las colecciones: DA - CIMA - Terapia génica y Hepatología - Oncobiología - Artículos de revista
DA - CIMA - Unidad de Proteómica, Genómica y Bioinformática - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Hepatología bioquímica - Artículos de revista

Ficheros en este registro:
Fichero:  AnnNeurol200660323.pdf
Descripción: 
Tamaño:  687,18 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.